Gene of the month: PTEN

Journal of Clinical Pathology

Volumn 65, Issue 7, 2012, Pages 601-603

  Govender, Dhirendra ^a   Chetty, Runjan ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CETUXIMAB; CYCLIN D1; FAS LIGAND; I KAPPA B; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAD; PROTEIN P27; PROTEIN P53; TRANSCRIPTION FACTOR FKHRL1; TRASTUZUMAB; TUBERIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; DOWN REGULATION; ENDOMETRIUM CARCINOMA; ENZYME ACTIVITY; ENZYME INACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE LOSS; GENE MUTATION; GENE STRUCTURE; GLIOBLASTOMA; GLIOMA; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN INTERACTION; PROTEIN PROCESSING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG THERAPY; HUMANS; MUTATION; NEOPLASMS; PTEN PHOSPHOHYDROLASE;

EID: 84863586560     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-200711     Document Type: Article

References (56)

1. Li D, Sun H. TEP 1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997;57:2124-9. (Pubitemid 27247025)
2. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7. (Pubitemid 27148818)
3. Steck P, Pershouse M, Jasser S, et al. Identification of a candidate tumor suppressor gene, MMCA1, at chromosome 10q23.3 that is mutated in multiple advanced cancer. Nat Genet 1997;15:356-62. (Pubitemid 27147102)
4. Di Cristofano A, Pandolfi P. The multiple roles of PTEN in tumor suppression. Cell 2000;100:387-90.
5. Georgescu MM. PTEN tumor suppressor network in PI3K-Akt pathway control. Genes Cancer 2010;1:1170-7.
6. Myers M, Stolarov J, Eng C, et al. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A 1997;94:9052-7.
7. Stambolic V, Suzuki A, de la Pompa J, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:1-20.
8. Engelman J, Luo J, Cantley L. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-19. (Pubitemid 44100518)
9. Manning B, Cantley L. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-74. (Pubitemid 46962095)
10. Freeman D, Li A, Wei G, et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and independent mechanisms. Cancer Cell 2003;3:117-30. (Pubitemid 37443385)
11. Mayo L, Donner D. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci 2002;27:462-7. (Pubitemid 35246255)
12. Cantley L. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-7. (Pubitemid 34579158)
13. Weng L, Brown J, Eng C. PTEN coordinates G1 arrest by down regulating cyclin D1 via its protein phosphatase activity and up regulating p27 via its lipid phosphatase activity. Hum Mol Genet 2001;10:599-604. (Pubitemid 32229364)
14. Baker S. PTEN enters the nuclear age. Cell 2007;128:25-8. (Pubitemid 46048899)
15. Shen W, Balajee A, Wang J, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007;128:157-70. (Pubitemid 46048887)
16. Ong S, Hadari Y, Gotoh N, et al. Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc Natl Acad Sci USA 2001;22:6074-9. (Pubitemid 32488195)
17. Takahashi-Tezuka M, Yoshida Y, Fukada T, et al. Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to ERK mitogen-activated protein kinase. Mol Cell Biol 1998;18:4109-17. (Pubitemid 28287934)
18. Yart A, Laffargue M, Mayeux P, et al. A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor. J Biol Chem 2001;276:8856-64.
19. Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C-terminus: implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 2001;276:993-8. (Pubitemid 32096519)
20. Trotman L, Wang X, Alimonti A, et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 2007;128:141-56. (Pubitemid 46048885)
21. Wu W, Wang X, Zhang W, et al. Zinc-induced PTEN\protein degradation through the proteasome pathway in human airway epithelial cells. J Biol Chem 2003;278:28258-63. (Pubitemid 36900027)
22. Perren A, Komminoth P, Saremaslani P, et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol 2000;157:1097-103.
23. Silva A, Yunes J, Cardoso B, et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008;118:3762-74.
24. Das S, Dixon J, Cho W. Membrane-binding and activation mechanism of PTEN. Proc Natl Acad Sci USA 2003;100:7491-6. (Pubitemid 36759997)
25. Torres J, Rodriguez J, Myers M, et al. Phosphorylation regulated cleavage of the tumor suppressor PTEN by caspase-3: implications for the control of protein stability and PTEN-protein interactions. J Biol Chem 2003;278:30652-60. (Pubitemid 36994570)
26. Vazquez F, Ramaswamy S, Nakamura N, et al. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 2000;20:5010-18. (Pubitemid 30431555)
27. Wang X, Trotman L, Koppie T, et al. NEDD4-1 is a proto oncogenic ubiquitin ligase for PTEN. Cell 2007;128:129-39. (Pubitemid 46048884)
28. Eng C. PTEN: one gene, many syndromes. Hum Mut 2003;22:183-98. (Pubitemid 37071635)
29. Han SY, Kato H, Suzuki T, et al. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res 2000;60:3147-51. (Pubitemid 30407908)
30. Waite K, Eng C. Protean PTEN: form and function. Am J Hum Genet 2002;70:829-44. (Pubitemid 34259300)
31. Salmena L, Carracedo A, Pandolfi P. Tenets of PTEN tumor suppression. Cell 2008;133:403-14. (Pubitemid 351622014)
32. Teng D, Hu R, Lin H, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997;57:5221-5. (Pubitemid 27516352)
33. Bose S, Wang S, Terry M, et al. Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene 1998;17:123-7. (Pubitemid 28360536)
34. Feilotter H, Nagai M, Boag A, et al. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 1998;16:1743-8. (Pubitemid 28175055)
35. Lin W, Forgacs E, Warshal D, et al. Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas. Clin Cancer Res 1998;4:2577-83. (Pubitemid 28523482)
36. Rubin M, Gerstein A, Reid K, et al. 10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3, N+) versus lymph node negative (pT2-3, N0) prostate cancer. Hum Pathol 2000;31:504-8. (Pubitemid 30262874)
37. Cairns P, Okami K, Halachmi S, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997;57:4997-5000. (Pubitemid 27498107)
38. Li XH, Zheng H-C, Takahashi H, et al. PTEN expression and mutation in colorectal carcinomas. Oncol Rep 2009;22:757-64.
39. Tashiro H, Blazes M, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935-40. (Pubitemid 27427679)
40. Wang S, Puc J, Li J, et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997;57:4183-6. (Pubitemid 27413419)
41. Saal L, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65:2554-9. (Pubitemid 40490050)
42. Zhou X, Loukola A, Salovaara R, et al. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol 2002;161:439-47. (Pubitemid 36142153)
43. Nelen M, van Staveren C, Peeters E, et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 1997;6:1383-7. (Pubitemid 27351082)
44. Liaw D, Marsh D, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997;16:64-7. (Pubitemid 27198157)
45. Marsh D, Dahia P, Zheng Z, et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 1997;16:333-4.
46. Zhou X, Hampel H, Thiele H, et al. Association of germline mutation in the PTEN tumour suppressor gene and a subset of Proteus and Proteus-like syndromes. Lancet 2001;358:210-11. (Pubitemid 32718548)
47. Mutter G, Lin MC, Fitzgerald J, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-31. (Pubitemid 30429193)
48. Zhou X, Kuismanen S, Nyström-Lahti M, et al. Distinct PTEN mutational spectra in endometrial carcinomas from hereditary non-polyposis colorectal cancer cases compared to sporadic microsatellite unstable tumors. Mol Genet 2002;11:445-50. (Pubitemid 34213618)
49. Kong D, Suzuki A, Zou TT, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 1997;17:143-4.
50. Zhou X, Li Y, Hoang-Xuan K, et al. Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer 2000;84:150-4. (Pubitemid 29133826)
51. Podsypanina K, Ellenson L, Nemes A, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999;96:1563-8. (Pubitemid 29098491)
52. Saal L, Johansson P, Holm K, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007;104:7564-9. (Pubitemid 47185946)
53. Pappas G, Zumstein L, Munshi A, et al. Adenoviral-mediated PTEN expression radiosensitizes non-small cell lung cancer cells by suppressing DNA repair capacity. Cancer Gene Ther 2007;14:543-9. (Pubitemid 46788333)
54. Jin H, Xu C, Kim H, et al. Urocanic acid-modified chitosan mediated PTEN delivery via aerosol suppressed lung tumorigenesis in K-ras(LA1) mice. Cancer Gene Ther 2008;15:275-83. (Pubitemid 351508133)
55. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27. (Pubitemid 39485684)
56. Neshat M, Mellinghoff I, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001;98:10314-19. (Pubitemid 32803017)